Roy Strowd, MD
Neurology · Winston Salem, NCNPI 1982830998
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $17,603 of the $21,699 with a category attached, or 81.1%. 8 manufacturers reported payments, led by Monteris Medical Corporation at 31.8% of the total. Reporting peaked in 2022 at $9,215 and has fallen 62.3% since, to $3,478 in 2025.
Across 35 payments — averaging $619.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Monteris Medical Corporation$7K
- Novocure Inc.$5K
- AstraZeneca$3K
- Springworks Therapeutics, Inc.$3K
- Catalyst Pharmaceuticals, Inc.$2K
- Biogen$1K
- plus $405 from 2 others
Across 270 payments — averaging $3390.34 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Incyte Corporation$457K
- Merck$317K
- Jazz Pharmaceuticals Inc.$80K
- UCB SA$30K
- AstraZeneca$26K
- Monteris Medical Corporation$6K
What the payments were for
- Consulting fees$17,60381%
- Speaking & faculty fees$2,25010%
- Travel & lodging$600%
- Food & beverage$1,7288%
- Education$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Monteris Medical Corporation | 8 | $6,895 |
| Novocure Inc. | 14 | $4,745 |
| AstraZeneca | 2 | $3,180 |
| Springworks Therapeutics, Inc. | 3 | $2,858 |
| Catalyst Pharmaceuticals, Inc. | 2 | $2,367 |
| Biogen | 1 | $1,250 |
| Jazz Pharmaceuticals Inc. | 4 | $346 |
| Greenwich Biosciences, Inc. | 1 | $59 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$21,699 in reported general payments places this provider in the 85th percentile of 566 neurology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 12 | $220,879 |
| Levetiracetam | 35 | $1,230 |
| Mycophenolate Mofetil | 11 | $1,153 |
| Lacosamide | 11 | $716 |
| Dexamethasone | 22 | $503 |
| Gabapentin | 19 | $262 |
| Ondansetron Hcl | 16 | $53 |
Paid to pharmacies, not to this prescriber.
Other neurology in Winston Salem
- Mustafa SiddiquiWinston Salem$162K
- Rachana Gandhi MehtaWinston Salem$94K
- David HosfordWinston Salem$90K
- Edward HillWinston Salem$50K
- Deepal Shah-ZamoraWinston Salem$42K
- Jill ConwayCharlotte$1M
- Matthew CarraroCharlotte$695K
- Richard SaterGreensboro$682K
- Sara SaccoMatthews$651K
- Megan DonnellyCharlotte$601K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.